% | $
Quotes you view appear here for quick access.

Achillion Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • macugen_rules macugen_rules Mar 31, 2012 2:21 PM Flag

    My Take

    I would also appreciate if someone with more knowledge in the HepC field to post some concrete Data regarding Medivir's ASPIRE Phase IIb Trial. It would be also interesting to see what Medivir Abstracts look like. Medivir has commenced Phase III testing of TMC435. So if someone has the Data sheet from the ASPIRE Phase IIB vs ACH-1625 in Phase 2a; I would like to see the charts comparison.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Never give up!.
      Medivir reports HCV drug study positive results
      Published 22 February 2011

      Medivir has reported positive results from the Phase 2b study of TMC435 in treatment-naïve patients with hepatitis C virus (HCV) genotype-1.
      The study results showed that TMC435 was safe and well-tolerated with no clinically relevant differences in adverse events between treatment groups and standard of care.
      In the treatment arm, 83% of patients were able to stop all therapy at week 24.
      Patients in the treatment arm demonstrated potent and consistent antiviral efficacy, with sustained virologic response (SVR) rates of up to 84%
      The phase 2b response guided study enrolled 386 treatment-naïve patients who were grouped into treatment arm or placebo arm.
      Patients in the treatment arm received TMC435, 75mg or 150mg, in combination with ribavirin and pegIFNalpha-2A, the current standard of care (SoC), while patients in the placebo arm received SoC plus placebo.

      The Ball is back to Achillion's court. 83% cure rate for TMC435+SOC!.

8.28-0.41(-4.72%)Jul 27 3:59 PMEDT